Comparative Pharmacology
Head-to-head clinical analysis: ARAKODA versus HYDROXYCHLOROQUINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAKODA versus HYDROXYCHLOROQUINE.
ARAKODA vs Hydroxychloroquine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Hydroxychloroquine is a 4-aminoquinoline antimalarial agent that accumulates in lysosomes and inhibits Toll-like receptor signaling, reduces cytokine production, and interferes with antigen presentation. It also inhibits heme polymerase in malarial parasites, leading to toxic heme accumulation.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
400 mg orally once daily or 200 mg orally twice daily, then 200-400 mg orally once daily for maintenance, depending on indication.
None Documented
None Documented
Clinical Note
moderateHydroxychloroquine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine."
Clinical Note
moderateHydroxychloroquine + Artemether
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether."
Clinical Note
moderateHydroxychloroquine + Chloroquine
"The serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine."
Clinical Note
moderateTerminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Terminal half-life: 30-60 days (prolonged due to extensive tissue binding); clinical context: requires loading dose for rapid effect.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Primarily renal (30-60% unchanged); minor hepatic metabolism; fecal elimination accounts for ~20-30%.
Category C
Category A/B
Antimalarial
Antimalarial / DMARD
Hydroxychloroquine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lumefantrine."